Binds Oligosaccharide Structure Patents (Class 530/387.5)
-
Publication number: 20130295100Abstract: The present invention relates to a method for predicting the risk of developing acute kidney injury in a subject from which a biological sample is obtained comprising: detecting the presence of at least one genomic single nucleotide polymorphism (SNP) selected from the group of: ADD1 rs4961 Trp [allelic genotype GT or TT], ADD2 rs4984 [allelic genotype CT or TT], HS-D3B1 rs2236780 [allelic genotype GG], LSS rs914247 [allelic genotype AA], MDR1 rs1045642 [allelic genotype TC or CC], SLC8A1 rs1 1893826 [allelic genotype AA], TRPC6 rs7925662 [allelic genotype CC] from said biological sample, wherein the presence of said allelic genotype is predictive of the risk of developing acute kidney injury.Type: ApplicationFiled: November 21, 2011Publication date: November 7, 2013Applicant: OSPEDALE SAN RAFFAELE S.R.L.Inventors: Paolo Manunta, Lorena Citterio, Giovanni Guglielmo Landoni, Elena Giovanna Bignami, Elisabetta Messaggio
-
Publication number: 20130281317Abstract: Nucleic acid constructs for expressing an antibody on the surface of bacteriophage are disclosed, as are methods for using the constructs to identify antibodies that target glycans.Type: ApplicationFiled: November 23, 2011Publication date: October 24, 2013Applicant: Allbert Einstein College of Medicine of Yeshiva UniversityInventors: Jonathan R. Lai, Alex Stewart
-
Publication number: 20130273097Abstract: Provided are immunogenic compositions and methods for eliciting an immune response against B. anthracis and other bacteria that contain 3-methyl-3-hydroxybutyrate- or 3-hydroxybutryate-substituted saccharides. Conjugates of 3-methyl-3-hydroxybutyrate- or 3-hydroxybutryate-substituted saccharides elicit an effective immune response against B. anthracis spores in mammalian hosts to which the conjugates are administered.Type: ApplicationFiled: June 4, 2013Publication date: October 17, 2013Inventors: Joanna Kubler-Kielb, Evguenii Vinogradov, Rachel Schneerson, Haijing Hu, Stephen H. Leppla, John B. Robbins
-
Publication number: 20130273074Abstract: The present invention provides methods and compositions useful in the field of medicine, and particularly in the treatment of inflammatory disorders. More particularly, the invention relates to the use of methods and compositions for the treatment and prevention of disorders associated with inflammation of alimentary tract, such as human immunodeficiency virus (HIV) infection and ulcerative colitis and Crohn's disease.Type: ApplicationFiled: October 4, 2011Publication date: October 17, 2013Applicant: IMMURON LIMITEDInventors: Grant Thomas Rawlin, Zeil Rosenberg, Oren Fuerst
-
Publication number: 20130243751Abstract: A conjugate molecule comprising an oligo- or polysaccharide covalently bound to a carrier and its use as potential vaccine against infection by S. Flexneri.Type: ApplicationFiled: December 14, 2011Publication date: September 19, 2013Inventors: Armelle PHALIPON, Farida Nato, Laurence Mulard, Philippe Sansonetti, Françoise Baleux, Frédéric Belot, Cyrille Grandjean
-
Patent number: 8518403Abstract: A composite polypeptide, said composite polypeptide comprising a desired polypeptide and an expression enhancing domain (“EED”), said EED comprising first and second cysteine amino acid residues Cys1 and Cys2, respectively, Cys1 being located closer to the N-terminus of the composite polypeptide molecule than Cys2, wherein Cys1 and Cys2 are separated by a polypeptide linker, said linker—being free of cysteine and proline;—defining a length sufficient to allow Cys1 and Cys2 to engage in an intramolecular disulfide bond with one another; and—having a flexible polypeptide conformation essentially free of secondary polypeptide structure in aqueous solution, wherein at least one of Cys1 and Cys2 is derivatized with a derivatization moiety.Type: GrantFiled: July 15, 2005Date of Patent: August 27, 2013Assignee: Amgen Research (Munich) GmbHInventors: Patrick Hoffmann, Silke Mittelstrass, Jens Hennecke, Tobias Raum
-
Publication number: 20130217031Abstract: The present invention provides a novel glyceroglycolipid produced by Mycoplasma pneumoniae. The glyceroglycolipid can be used as a diagnostic marker for a disease caused by Mycoplasma pneumoniae.Type: ApplicationFiled: December 28, 2012Publication date: August 22, 2013Applicant: M BIO TECHNOLOGY INC.Inventor: M BIO TECHNOLOGY INC.
-
Publication number: 20130216576Abstract: Disclosed is a new and emerging serotype of Streptococcus pneumoniae designated serotype 6D, and assays and monoclonal antibodies useful in identifying same. Also disclosed is a novel pneumococcal polysaccharide with the repeating unit?2) glucose 1 (1?3) glucose 2 (1?3) rhamnose (1?4) ribitol (5?phosphate. This new serotype may be included in pneumococcal vaccines.Type: ApplicationFiled: April 19, 2013Publication date: August 22, 2013Applicant: UAB Research FoundationInventor: UAB Research Foundation
-
Publication number: 20130210033Abstract: An object is to provide a biomarker specific to amyotrophic lateral sclerosis and a use thereof. Provided are a marker for amyotrophic lateral sclerosis containing a transmembrane glycoprotein nmb, and a method for detecting amyotrophic lateral sclerosis, which utilizes the marker, and the like.Type: ApplicationFiled: September 20, 2011Publication date: August 15, 2013Inventors: Hideaki Hara, Masamitsu Shimazawa, Hirotaka Tanaka
-
Publication number: 20130203968Abstract: Compositions and methods relating to sclerostin binding agents, such as antibodies and polypeptides capable of binding to sclerostin, are provided.Type: ApplicationFiled: April 1, 2013Publication date: August 8, 2013Applicants: UCB PHARMA S.A., AMGEN INC.Inventors: Amgen Inc., UCB Pharma S.A.
-
Publication number: 20130195873Abstract: Immunogenic compositions that contain haptens consisting of carbohydrate moieties are useful to induce an immune response to provide antibodies to epitopes contained in CA215 and also to elicit an immune response to cancers expressing these epitopes.Type: ApplicationFiled: July 14, 2011Publication date: August 1, 2013Applicant: Vancouver Biotech LTD.Inventor: Chi-Yu Gregory Lee
-
Publication number: 20130177551Abstract: Provided herein methods for determining whether a subject, particularly a human subject, is at risk of developing, having, or experiencing a complication of cardiovascular disease, and methods of treating subjects who are identified by the current methods of being at risk for cardiovascular disease. In one embodiment, the method comprises determining levels of one or more oxidized apolipoprotien A-I related biomolecules in a bodily sample from the subject. Also, provided are kits and reagents for use in the present methods. Also provided are methods for monitoring the status of cardiovascular disease in a subject or the effects of therapeutic agents on subjects with cardiovascular disease. Such method comprising determining levels of one or more oxidized apolipoprotein A-I related molecules in bodily samples taken from the subject over time or before and after therapy.Type: ApplicationFiled: November 21, 2012Publication date: July 11, 2013Inventors: Stanley L. Hazen, Michael Kinter, Marc S. Penn, Jonathan Smith, Lemin Zheng
-
Publication number: 20130171147Abstract: The present invention is directed to the neutralizing prolactin receptor antibody 002-H06, and antigen binding fragments, pharmaceutical compositions containing them and their use in the treatment or prevention of benign disorders and indications mediated by the prolactin receptor such as endometriosis, adenomyosis, non-hormonal female contraception, benign breast disease and mastalgia, lactation inhibition, benign prostate hyperplasia, fibroids, hyper- and normoprolactinemic hair loss, and cotreatment in combined hormone therapy to inhibit mammary epithelial cell proliferation. The antibodies of the invention block prolactin receptor-mediated signaling.Type: ApplicationFiled: November 18, 2010Publication date: July 4, 2013Applicant: BAYER INTELLECTUAL PROPERTY GMBHInventors: Christiane Otto, Siegmund Wolf, Christoph Freiberg, Axel Harrenga, Simone Greven, Mark Trautwein, Sandra Bruder
-
Patent number: 8476409Abstract: Provided are bispecific antibodies that are useful as anti-neoplastic agents and that bind specifically to human IGF-1R and human ErbB3. Exemplary antibodies inhibit signal transduction through either or both of IGF-1R and ErbB3.Type: GrantFiled: April 19, 2012Date of Patent: July 2, 2013Assignee: Merrimack Pharmaceuticals, Inc.Inventors: Jason Baum, Bryan Johnson, Alexey Alexandrovich Lugovskoy, Lihui Xu, Neeraj Kohli, Jonathan Basil Fitzgerald, Sharlene Adams
-
Publication number: 20130164216Abstract: Provided in the present invention are an aberrantly glycosylated integrin, AG-?3?1, and use thereof as a bladder cancer marker. Also provided in the present invention are a hybridoma cell generating an anti-AG-?3?1 monoclonal antibody, a monoclonal antibody BCMab1 secreted by the same, and use of BCMab1 in the preparation of a medicament for the treatment of bladder cancer. Also provided in the present invention is use of inhibitors of GAL3ST2 and N-acetylgalactosaminyltransferase 1 in the preparation of a medicament for the treatment of bladder cancer.Type: ApplicationFiled: August 12, 2011Publication date: June 27, 2013Applicant: Institute Of Biophysics, Chinese Academy Of SciencesInventors: Chong Li, Zusen Fan, Honglian Zhang, Zhonghua Dai, Haidong Tang, Jun Chen
-
Publication number: 20130156696Abstract: The invention described herein provides for human antibodies produced in non-human animals that specifically bind to Pseudomonas aeruginosa Lipopolysaccharide (LPS). The invention further provides methods for making the antibodies in a non-human animal, expression of the antibodies in cell lines including hybridomas and recombinant host cell systems. Also provided are kits and pharmaceutical compositions comprising the antibodies and methods of treating or preventing pseudomonas infection by administering to a patient the pharmaceutical compositions described herein.Type: ApplicationFiled: May 27, 2011Publication date: June 20, 2013Applicant: CASE WESTERN RESERVE UNIVERSITYInventors: John R. SCHREIBER, Kulwant KAUR
-
Patent number: 8461305Abstract: Disclosed is a novel lectin which can bind specifically to an L-fucose ?1?6 sugar chain. Also disclosed is use of the lectin. The L-fucose ?1?6 specific lectin of the present invention is characterized in that: (1) the lectin is extracted from a basidiomycete or an ascomycete; (2) the lectin has a molecular weight by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) of 4,000 to 40,000; and (3) the lectin has an affinity to an L-fucose ?1?6 sugar chain, the affinity being represented by an association constant of 1.0×104M?1 or more (at 25 degrees C.). The lectin can be used for detecting an L-fucose ?1?6 sugar chain specifically, and is effective for the purification of an L-fucose ?1?6 sugar chain or a non L-fucose ?1?6 sugar chain.Type: GrantFiled: July 15, 2009Date of Patent: June 11, 2013Assignees: J-Oil Mills, Inc., National Institute of Advanced Industrial Science and Technology, National University Corporation Shizuoka UniversityInventors: Yuka Kobayashi, Jun Hirabayashi, Hiroaki Tateno, Hirokazu Kawagishi, Hideo Dohra
-
Publication number: 20130129736Abstract: The present invention relates to a method for the in vitro determination of the presence of or a predisposition of a patient to the development of cancer. In the method according to the invention, the presence of a marker is determined in a biological sample of the patient, said marker being selected from a) the amino acid sequence SEQ ID Nr. 2 from the sequence protocol that is provided, or b) a nucleic acid that encodes the amino acid sequence with the SEQ ID Nr. 2. The invention further relates to the amino acid and the encoding nucleic acid and to the use thereof in diagnostics and for molecular therapeutic approaches.Type: ApplicationFiled: January 29, 2013Publication date: May 23, 2013Applicant: Eberhard-Karls-Universit.t Tubingen Universit. tsklinikumInventor: Eberhard-Karls-Universit.t Tubingen Universit.tsklinikum
-
Publication number: 20130115627Abstract: The disclosure relates to methods for screening candidate antibody molecules which bind to podocalyxin-like protein (PODXL) and/or to undifferentiated pluripotent stem cells and particularly, although not exclusively, to methods for identifying candidate cytotoxic antibody molecules.Type: ApplicationFiled: July 21, 2011Publication date: May 9, 2013Applicant: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCHInventor: Boon Hwa Andre Choo
-
Publication number: 20130115612Abstract: The object of the present invention is to provide a clinical marker capable of distinguishing breast cancer from interstitial pneumonia; and a clinical marker for detecting malignancy or progress level of breast cancer, and for monitoring effects of the treatment of breast cancer. The object can be solved by a method for analyzing mucin 1 having Sia?2-8Sia?2-3Gal?-R, characterized by comprising the step of bringing a first probe specifically binding to a mucin 1 having Sia?2-8Sia?2-3Gal?-R into contact with a sample to be tested.Type: ApplicationFiled: May 6, 2011Publication date: May 9, 2013Applicants: YAMAGUCHI UNIVERSITY, TOKYO INSTITUTE OF TECHNOLOGYInventors: Katsuko Yamashita, Keiko Fukushima, Yuji Hinoda
-
Publication number: 20130108636Abstract: The invention provides engineered antibody domains (eAds), a polypeptide comprising a single domain CD4, as well as a fusion protein comprising the same. Nucleic acids encoding eAd and/or polypeptide or the fusion protein thereof, as well as compositions or cells comprising the eAd, polypeptide, fusion protein, or nucleic acid also are provided.Type: ApplicationFiled: May 20, 2011Publication date: May 2, 2013Inventors: Dimiter S. Dimitrov, Weizao Chen
-
Publication number: 20130108624Abstract: The present invention relates to a novel glycan marker of cancer and monoclonal antibodies against it. Furthermore, novel glycan markers and their use in the detection and monitoring of cancerous cells and cancer-associated or specific antibody signatures are described.Type: ApplicationFiled: December 3, 2012Publication date: May 2, 2013Applicants: Imperial College of London, The Board of Trustees of the Leland Stanford Junior UniversityInventors: The Board of Trustees of the Leland Stanford Junior University, Imperial College of London
-
Publication number: 20130101587Abstract: Immunoglobulin chains or antibodies having light or heavy chain complementarity determining regions of antibodies that bind to P-Selectin Glycoprotein Ligand-1. Also disclosed are methods of inducing death of an activated T-cell and of modulating a T cell-mediated immune response in a subject.Type: ApplicationFiled: September 14, 2012Publication date: April 25, 2013Applicant: AbGenomics Cooperatief U.A.Inventors: Rong-Hwa Lin, Chung Nan Chang, Pei-Jiun Chen, Chiu-Chen Huang
-
Publication number: 20130084276Abstract: The invention relates to differentially expressed disease - associated proteins that have potential to identify patients with cardiovascular disease including ventricular dysfunction and heart failure and the potential to predict heart failure in patients. In particular, the invention relates to the use of a panel of biomarkers in the diagnostic and prognostic evaluation of cardiovascular patients. One of the markers is Leucine-rich alpha-2-glycoprotein (LRG).Type: ApplicationFiled: January 26, 2011Publication date: April 4, 2013Inventors: Chris Watson, Mark Ledwidge, Kenneth McDonald, John Baugh
-
Publication number: 20130078251Abstract: The invention provides anti-MCSP antibodies and methods of using the same.Type: ApplicationFiled: August 21, 2012Publication date: March 28, 2013Inventors: Olivier Freytag, Guy Georges, Ekkehard Moessner, Olaf Mundigl, Gérald Tuffin, Pablo Umana
-
Publication number: 20130071951Abstract: This application describes an antibody that specifically binds to a synthetic oligomer (e.g., an oligonucleotide or oligopeptide) having a organic protecting group covalently bound thereto, which antibody does not bind to that synthetic oligomer when the organic protecting group is not covalently bound thereto. Methods of making and using such antibodies are also disclosed, along with cells for making such antibodies and articles carrying immobilized oligomers that can be used in assay procedures with such antibodies.Type: ApplicationFiled: November 6, 2012Publication date: March 21, 2013Inventors: Paul F. Agris, Christipher D.J. Pearce, Lloyd G. Mitchell
-
Publication number: 20130052197Abstract: The invention provides a therapeutic agent for autoimmune diseases, particularly type 1 diabetes and rheumatoid arthritis, as well as a method of preparing the therapeutic agent and a method of treating an autoimmune disease with the therapeutic agent. The therapeutic agent is an anti-CD98 antibody that does not inhibit amino acid transport of CD98 but has a suppressive action on T lymphocyte activation, a suppressive action on cell adhesion mediated by fibronectin, as well as an OVA antibody production suppressive action in OVA immunization model.Type: ApplicationFiled: March 25, 2011Publication date: February 28, 2013Applicant: THE UNIVERSITY OF TOKUSHIMAInventor: Koji Yasutomo
-
Publication number: 20130045207Abstract: Provided is a novel antibody having an excellent antibacterial activity against P. aeruginosa. By using plasmablasts obtained from cystic fibrosis patients with chronic P. aeruginosa pulmonary infection as starting materials, antibodies which bind to LPS of a P. aeruginosa strain of serotype G and which have excellent antibacterial activities in vitro and in vivo were successfully obtained.Type: ApplicationFiled: February 18, 2011Publication date: February 21, 2013Applicants: SYMPHOGEN A/S, MEIJI SEIKA PHARMA CO., LTD.Inventors: Jiro Tanaka, Peter Sejer Andersen, Takafumi Okutomi, Tsuneyoshi Inaba, Keiko Otsuka, Hirotomo Akabane, Yukari Hoshina, Hiroshi Nagaso, Masashi Kumagai
-
Publication number: 20130045543Abstract: An objective of the present invention is to provide a MUC1 antibody having high specificity to cancer cells. The objective has been achieved by the present inventors who found that a cancer-specific sugar chain can be specifically recognized in MUC1 and a cancer cell expressing MUC1 having such a cancer cell specific sugar chain can be recognized. The present invention provides an antibody, an antigen-binding fragment thereof or a MUC1-binding molecule, having, for example, 40-fold specificity or more for a cancer-associated structure of MUC1 as compared to that of a normal tissue-associated structure of MUC1.Type: ApplicationFiled: April 28, 2011Publication date: February 21, 2013Inventors: Shin-Ichiro Nishimura, Shoichi Naito, Naoki Ohyabu, Tatsuya Takahashi, Yoshito Numata
-
Publication number: 20130034556Abstract: An isolated or purified compound is provided, comprising A-GlcNAc[GlcNAc]-GalNAc-GalNAc-QuiNAc4NAc, wherein A is GlcNAc or Glc. There is further provided a vaccine based on such compound, having particular use to treat or prevent an infection caused by a Campylobacter organism. There is also provided an antibody or antisera against the compound, having particular use to diagnose the presence of an infection caused by a Campylobacter organism.Type: ApplicationFiled: February 11, 2011Publication date: February 7, 2013Applicant: The Governors of the University of AlbertaInventors: Christine Szymanski, Harald Nothaft
-
Publication number: 20130034557Abstract: Cancer-associated O-glycopeptide combination epitopes derived from the VNTR of MUC1 are disclosed. Autoantibodies present in human sera target the combination epitopes and are reduced or absent in cancer patients. The epitopes are useful as therapeutic and immunoprophylactic cancer vaccines. Monoclonal antibodies directed against the epitopes are also useful as immunotherapeutics for treatment and prevention of cancer. Diagnostic methods using the epitopes and antibodies are also disclosed.Type: ApplicationFiled: April 15, 2011Publication date: February 7, 2013Applicant: EZOSE SCIENCES, INC.Inventors: Shin-Ichiro Nishimura, Takahiko Matsushita, Yoshiaki Miura
-
Publication number: 20130022604Abstract: Provided is a novel antibody having an excellent antibacterial activity against P. aeruginosa. By using plasmablasts obtained from cystic fibrosis patients with chronic P. aeruginosa pulmonary infection as starting materials, antibodies which bind to LPS of a P. aeruginosa strain of serotype B and which have excellent antibacterial activities in vitro and in vivo were successfully obtained.Type: ApplicationFiled: February 18, 2011Publication date: January 24, 2013Applicants: SYMPHOGEN A/S, MEIJI SEIKA PHARMA CO., LTD.Inventors: Jiro Tanaka, Peter Sejer Andersen, Takafumi Okutomi, Tsuneyoshi Inaba, Keiko Otsuka, Hirotomo Akabane, Yukari Hoshina, Hiroshi Nagaso, Masashi Kumagai
-
Publication number: 20130022603Abstract: Provided is a novel antibody having an excellent antibacterial activity against P. aeruginosa. By using plasmablasts obtained from cystic fibrosis patients with chronic P. aeruginosa pulmonary infection as starting materials, antibodies which bind to LPS of a P. aeruginosa strain of serotype I and which have excellent antibacterial activities in vitro and in vivo were successfully obtained.Type: ApplicationFiled: February 18, 2011Publication date: January 24, 2013Applicants: SYMPHOGEN A/S, MEIJI SEIKA KAISHA, LTD.Inventors: Jiro Tanaka, Peter Sejer Andersen, Takafumi Okutomi, Tsuneyoshi Inaba, Keiko Otsuka, Hirotomo Akabane, Yukari Hoshina, Hiroshi Nagaso, Masashi Kumagai
-
Publication number: 20130017561Abstract: Fungal infections are difficult to diagnose. The most common filamentous fungal infection, aspergillosis, carries with it a high mortality. Culture of the organism is difficult and obtaining samples, e.g., though a lung biopsy, sometimes causes morbidity. Biomarkers that indicate ‘early’ infection in it development are sought after. One such biomarker is detection of galactomannan (GM), a polysaccharide that is attached to hyphal cell walls and secreted during growth of the organism. Galactomannan is excreted in urine. Disclosed herein is a lateral flow assay comprising monoclonal antibodies that recognize specific residues of Aspergillus fumigates for detecting GM in urine samples to provide a point-of-care detection device to allow for frequent screening and early diagnosis in patients at high risk for infection.Type: ApplicationFiled: November 23, 2010Publication date: January 17, 2013Applicants: YESHIVA UNIVERSITY, THE JOHNS HOPKINS UNIVERSITYInventors: Kieren A. Marr, Janet F. Staab, Marta Feldmesser
-
Publication number: 20130004500Abstract: Provided is a novel antibody having an excellent antibacterial activity against P. aeruginosa. By using plasmablasts obtained from cystic fibrosis patients with chronic P. aeruginosa pulmonary infection as starting materials, antibodies which bind to LPS of a P. aeruginosa strain of serotype A and which have excellent antibacterial activities in vitro and in vivo were successfully obtained.Type: ApplicationFiled: February 18, 2011Publication date: January 3, 2013Applicants: SYMPHOGEN A/S, MEIJI SEIKA PHARMA CO., LTD.Inventors: Jiro Tanaka, Peter Sejer Andersen, Takafumi Okutomi, Tsuneyoshi Inaba, Keiko Otsuka, Hirotomo Akabane, Yukari Hoshina, Hiroshi Nagaso, Masashi Kumagai
-
Publication number: 20130004943Abstract: The invention provides monoclonal antibodies and related binding proteins that bind specifically to the envelope glycoprotein of H5 subtypes of avian influenza virus (“AIV”). The monoclonal antibodies and related binding proteins are useful for the detection of H5 subtypes of AIV, including the pathogenic H5N1 subtypes. Virus may be detected in formalin preserved, paraffin embedded specimens as well as frozen specimens and biological fluids. Accordingly, the invention provides means for the diagnosis and surveillance of dangerous viral infections.Type: ApplicationFiled: September 13, 2012Publication date: January 3, 2013Applicant: TAMASEK LIFE SCIENCES LABORATORY LIMITEDInventors: Yuen Fern Ho, Qing Yun Du, Fang He, Jimmy Hwei-Sing Kwang
-
Publication number: 20130004499Abstract: Provided is a novel antibody having an excellent antibacterial activity against P. aeruginosa. By using plasmablasts obtained from cystic fibrosis patients with chronic P. aeruginosa pulmonary infection as starting materials, antibodies which bind to LPS of a P. aeruginosa strain of serotype E and which have excellent antibacterial activities in vitro and in vivo were successfully obtained.Type: ApplicationFiled: February 18, 2011Publication date: January 3, 2013Applicants: SYMPHOGEN A/S, Meiji Seika Pharma Co., Ltd.Inventors: Jiro Tanaka, Peter Sejer Andersen, Takafumi Okutomi, Tsuneyoshi Inaba, Keiko Otsuka, Hirotomo Akabane, Yukari Hoshina, Jun Saito, Hiroshi Nagaso, Masashi Kumagai, Yasuyo Hagiwara
-
Patent number: 8323644Abstract: A therapeutic composition for treatment of cancer in a mammal is disclosed. The composition comprises an effective amount of a yeast beta-glucan composition which is suitable for oral administration and for absorption through the gastrointestinal tract of the mammal. The above therapeutic composition may further comprise antitumor antibodies or cancer vaccine composition, wherein the antitumor activities of the antitumor antibodies or the cancer vaccine composition are enhanced by the yeast glucan.Type: GrantFiled: January 17, 2007Date of Patent: December 4, 2012Assignees: Sloan-Kettering Institute for Cancer Research, Biotec Pharmacon ASAInventors: Nai-Kong V. Cheung, Rolf Einar Engstad
-
Publication number: 20120294864Abstract: The present application relates to compositions of humanized and humanized/deimmunized anti-endoglin antibodies and antigen-binding fragments thereof. One aspect relates to antibodies having one or more modifications in at least one amino acid residue of at least one of the framework regions of the variable heavy chain, the variable light chain or both. Another aspect relates to antibodies which bind endoglin and inhibit angiogenesis. Another aspect relates to the deimmunization of humanized antibodies to reduce immunogenicity. Another aspect relates to the use of humanized and humanized/deimmunized antibodies which bind endoglin for the detection, diagnosis or treatment of a disease or condition associated with endoglin, angiogenesis or a combination thereof.Type: ApplicationFiled: May 31, 2012Publication date: November 22, 2012Applicant: TRACON PHARMACEUTICALS, INC.Inventors: Charles Theuer, Maximiliano Vasquez
-
Patent number: 8298779Abstract: The invention involves assays, diagnostics, kits, and assay components for determining levels of K41-glycated CD59 in subjects. Treatments for subjects based upon levels of K41-glycated CD59 also are provided.Type: GrantFiled: August 9, 2011Date of Patent: October 30, 2012Assignee: President and Fellows of Harvard CollegeInventor: Jose A. Halperin
-
Publication number: 20120164145Abstract: Helicobacter pylori, one of the most common human pathogens, is associated with the development of human chronic gastritis, peptic ulcers and gastric cancer. The invention relates to a ?1,6-glucan-containing Helicobacter pylori compound comprising the structure of Formula (I): wherein R is a ?-DDHep-3-?-L-Fuc-3-?-GlcNAc trisaccharide substituted with an ?1,6-glucan linked to an ?1,3-DD-heptan, and wherein the last DD-Hep residue of ?1,3-DD-heptan is capped with ?-GlcNAc residue. Compositions comprising the compound, uses of the compound, and antibodies raised against the compound are also described.Type: ApplicationFiled: July 30, 2010Publication date: June 28, 2012Inventors: Eleanora Altman, Blair A. Harrison, Vandana Chandan
-
Patent number: 8198415Abstract: The invention relates to a method for manufacturing an anti-RhD recombinant polyclonal antibody composition (anti-RhD rpAb). The method comprises obtaining a collection of cells transfected with a library of anti-RhD antibody expression vectors, wherein each cell in the collection is capable of expressing from a VH and VL comprising nucleic acid segment, one member of the library, which encodes a distinct member of anti-RhD recombinant polyclonal antibody composition and which is located at the same site in the genome of individual cells in said collection. The cells are cultured under suitable conditions for expression of the recombinant polyclonal antibody, which is obtained from the cells or culture supernatant. The nucleic acid segments encoding the anti-RhD rpAb is introduced into the cells by transfection with a library of vectors for site-specific integration.Type: GrantFiled: July 18, 2005Date of Patent: June 12, 2012Assignee: Symphogen A/SInventors: Søren Kofoed Rasmussen, Anne Bondgaard Tolstrup, Søren Bregenholt Frederiksen, John Haurum
-
Publication number: 20120128676Abstract: The present invention pertains to anti-mucin antibodies having improved antigen binding and/or recognition properties as well as a method for improving the antigen binding and/or recognition of an anti-mucin antibody. In particular, the present invention is directed to anti-MUC1 antibodies which are useful in the treatment of cancer.Type: ApplicationFiled: July 30, 2010Publication date: May 24, 2012Applicant: GLYCOTOPE GMBHInventors: Steffen Goletz, Antje Danielczyk, Renate Stahn, Uwe Karsten
-
Publication number: 20120122126Abstract: An antibody which recognizes PSK is provided. The object of the present invention is solved by an antibody characterized by recognizing PSK and inhibiting anti-tumor activity of PSK. In particular, the inhibition of anti-tumor activity of PSK is an inhibition of cytotoxic activity or an inhibition of anti-TGF-?1 activity of PSK. A physiologically active PSK can, using the present invention, be detected high-accurately and quantitatively. For example, the present invention is useful for detecting and measuring the physiologically active PSK contained in a medicine or a food and drink, and for analyzing pharmacokinetics after administrating the physiologically active PSK.Type: ApplicationFiled: July 23, 2010Publication date: May 17, 2012Applicant: Kureha CorporationInventors: Hirotaka Hoshi, Hikaru Saito, Motoyuki Uchida
-
Patent number: 8148499Abstract: The invention relates to a vaccine for the treatment of disease caused by Neisseria, the vaccine comprising one or more immunogenic components for Neisseria serogroups, as well as antibodies to the immunogenic components and methods of preventing and treating Neisseria infections. The immunogens are based on elements of the inner core lipopolysaccharide.Type: GrantFiled: February 14, 2011Date of Patent: April 3, 2012Assignee: Isis Innovation Ltd.Inventors: Joyce Susan Plested, Michael Paul Jennings, Margaret Ann Jaqueline Gidney, Andrew David Cox, James Clare Richards, Edward Richard Moxon
-
Patent number: 8114633Abstract: The present invention relates, in general, to methods for detecting and quantitating plasma-derived protein and recombinant protein in a sample based on the difference in protein glycosylation, when the plasma protein and the recombinant protein are essentially the same protein.Type: GrantFiled: December 22, 2008Date of Patent: February 14, 2012Assignees: Baxter International Inc., Baxter Healthcare S.A.Inventors: Alfred Weber, Peter Turecek, Hans-Peter Schwarz
-
Publication number: 20120028359Abstract: The present invention relates to a production process of a gender-specific serum and a biomarker using the serum. More specifically, the present invention uses a fatty acid that exhibits a specific expression pattern in a gender-specific serum as a biomarker not only for diagnosis of obesity or a disease related to obesity, but also for diagnosis of meat quality since the fatty acid promotes differentiation of muscle derived stem cells into adipose cells. In addition, the present invention can establish a research system studying the effects of steroid hormones on the cell culture by using sera separated from blood that is collected from individual mammal carcasses being disposed, and provide important clues for discovering a gene associated with the synthesis of steroid hormone and for developing treatments for human diseases.Type: ApplicationFiled: April 6, 2010Publication date: February 2, 2012Inventors: In Ho Choi, Dong Mok Lee, Jong Soo Chang, Hyun Jeong Lee, Eun Ju Lee, Bajracharya Prati, Yu Mi Shin
-
Publication number: 20120027762Abstract: The present invention relates to a method of inducing an immune response to a parasite utilizing an immunogenic composition comprising a glycosylphosphatidylinositol (“GPI”) inositolglycan domain or its derivative or equivalent. The present invention is useful as a prophylactic and/or therapeutic treatment for microorganism infections of mammals such as parasite infections and particularly infection by Plasmodium species. The invention also provides a method of monitoring, or qualitatively or quantitatively assessing an immune response to a microorganism such as a parasite.Type: ApplicationFiled: September 22, 2011Publication date: February 2, 2012Applicant: The Walter and Eliza Hall Institute of Medical ResearchInventor: Louis Schofield
-
Publication number: 20120015385Abstract: Novel conjugates of doxorubicin and novel doxorubicin immunogens derived from the 13 and 14 positions of doxorubicin and antibodies generated by these doxorubicin linked immunogens all of which are useful in immunoassays for the quantification and monitoring of doxorubicin in biological fluids.Type: ApplicationFiled: September 23, 2011Publication date: January 19, 2012Inventors: Salvatore J. Salamone, Jodi Blake Courtney, Shu He
-
Patent number: 8088357Abstract: The invention relates to recognition molecules which are directed towards tumors and can be used in the diagnosis and therapy of tumor diseases.Type: GrantFiled: December 1, 2003Date of Patent: January 3, 2012Assignee: Nemod Biotherapeutics GmbH & Co. KGInventors: Steffen Goletz, Antje Danielczyk, Uwe Karsten, Peter Ravn, Renate Stahn, Peter Astrup Christensen